Free Trial

Belite Bio (BLTE) Competitors

Belite Bio logo
$61.85 -0.46 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$61.91 +0.06 (+0.10%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BLTE vs. LEGN, ELAN, RGC, RVMD, GRFS, TGTX, NUVL, RYTM, CRSP, and AXSM

Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Legend Biotech (LEGN), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

Belite Bio vs. Its Competitors

Legend Biotech (NASDAQ:LEGN) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Belite Bio has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$627.24M12.95-$177.03M-$0.59-74.93
Belite BioN/AN/A-$36.14M-$1.36-45.48

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Legend Biotech has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.5, indicating that its stock price is 250% less volatile than the S&P 500.

Belite Bio has a net margin of 0.00% compared to Legend Biotech's net margin of -29.95%. Legend Biotech's return on equity of -21.19% beat Belite Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Legend Biotech-29.95% -21.19% -13.47%
Belite Bio N/A -32.07%-30.91%

Legend Biotech presently has a consensus price target of $73.33, suggesting a potential upside of 65.87%. Belite Bio has a consensus price target of $96.67, suggesting a potential upside of 56.29%. Given Legend Biotech's higher possible upside, research analysts plainly believe Legend Biotech is more favorable than Belite Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Legend Biotech
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.91
Belite Bio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Legend Biotech had 10 more articles in the media than Belite Bio. MarketBeat recorded 12 mentions for Legend Biotech and 2 mentions for Belite Bio. Legend Biotech's average media sentiment score of 1.11 beat Belite Bio's score of -0.50 indicating that Legend Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Legend Biotech
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Belite Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

Summary

Legend Biotech beats Belite Bio on 10 of the 15 factors compared between the two stocks.

Get Belite Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLTE vs. The Competition

MetricBelite BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.98B$3.06B$5.70B$9.48B
Dividend YieldN/A2.37%4.59%3.99%
P/E Ratio-45.4820.7327.9019.95
Price / SalesN/A321.12442.19102.72
Price / CashN/A43.2336.5558.97
Price / Book13.108.308.635.90
Net Income-$36.14M-$55.19M$3.24B$258.42M
7 Day Performance1.41%5.07%3.22%1.94%
1 Month Performance3.64%17.61%10.72%12.02%
1 Year Performance28.53%7.03%34.94%20.81%

Belite Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLTE
Belite Bio
1.7601 of 5 stars
$61.85
-0.7%
$96.67
+56.3%
+24.4%$1.98BN/A-45.4810
LEGN
Legend Biotech
3.6979 of 5 stars
$42.23
+1.5%
$73.33
+73.7%
-26.0%$7.64B$627.24M-71.582,609Positive News
Analyst Revision
ELAN
Elanco Animal Health
3.5435 of 5 stars
$14.67
-0.8%
$16.00
+9.1%
+13.2%$7.34B$4.44B19.829,000Analyst Forecast
Analyst Revision
RGC
Regencell Bioscience
0.358 of 5 stars
$14.40
-0.7%
N/AN/A$7.17BN/A0.0010Gap Down
RVMD
Revolution Medicines
4.5858 of 5 stars
$38.42
+0.3%
$68.91
+79.4%
-19.8%$7.13B$11.58M-9.61250Positive News
GRFS
Grifols
3.426 of 5 stars
$10.00
+0.6%
$10.30
+3.0%
+27.1%$6.83B$7.81B8.5523,822Upcoming Earnings
TGTX
TG Therapeutics
3.7211 of 5 stars
$37.42
-1.3%
$43.80
+17.0%
+85.5%$6.02B$329M157.96290Positive News
NUVL
Nuvalent
3.3157 of 5 stars
$82.46
-1.1%
$119.60
+45.0%
-2.5%$5.99BN/A-18.7840Analyst Forecast
RYTM
Rhythm Pharmaceuticals
3.2498 of 5 stars
$88.63
-0.6%
$91.93
+3.7%
+76.3%$5.68B$130.13M-31.54140
CRSP
CRISPR Therapeutics
1.7589 of 5 stars
$65.33
+0.3%
$71.75
+9.8%
+19.1%$5.62B$37.31M-14.45460Analyst Forecast
Analyst Revision
High Trading Volume
AXSM
Axsome Therapeutics
4.7148 of 5 stars
$109.68
-1.8%
$172.33
+57.1%
+24.2%$5.50B$385.69M-19.01380Analyst Revision

Related Companies and Tools


This page (NASDAQ:BLTE) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners